{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:53:35Z","timestamp":1792086815891,"version":"4.4.0"},"reference-count":19,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2018-0108_s_001_w2aab3b7b2b1b6b1aab1c17b1Aa\">\n                    <jats:title id=\"d8956950e2892_w2aab3b7b2b1b6b1aab1c17b1aAa\">Background<\/jats:title>\n                    <jats:p>Peritoneal carcinomatosis (PC) is a common endpoint in both gastrointestinal and non-gastrointestinal cancers, and PC is treated as other systemic metastases \u2013 unfortunately with disappointing results and considerable side-effects. Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) is a new method of applying traditional chemotherapy, and preliminary data indicate that PIPAC is safe, able to stabilize or improve quality of life, and can induce an objectively measurable reduction in disease burden in PC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2018-0108_s_002_w2aab3b7b2b1b6b1aab1c17b2Aa\">\n                    <jats:title id=\"d8956950e2901_w2aab3b7b2b1b6b1aab1c17b2aAa\">Methods<\/jats:title>\n                    <jats:p>\n                      PIPAC-OPC2 is a prospectively controlled Phase II, single center, one-arm, open-label clinical trial investigating the treatment effect of PIPAC in patients with histological or cytological proven PC from gastrointestinal, ovarian or primary peritoneal cancer. Eligible patients will receive PIPAC in series of three using a combination of doxorubicin (1.5\u2006mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) and cisplatin (7.5\u2006mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) for non-colorectal cancer patients (PIPAC C\/D), and oxaliplatin (92\u2006mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) in patients with PC of colorectal origin (PIPAC OX). Patients are monitored by: (1) repeated measurements of the Peritoneal Regression Grading Score (PRGS) in biopsies obtained from metal clips marked areas, (2) Quality-of-Life (QoL) questionnaires, (3) Magnetic Resonance Imaging (MRI) and (4) Prognostic Nutritional Index (PNI). Adverse events and surgical complications will be recorded according to the 30 days definition.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2018-0108_s_003_w2aab3b7b2b1b6b1aab1c17b3Aa\">\n                    <jats:title id=\"d8956950e2919_w2aab3b7b2b1b6b1aab1c17b3aAa\">Results<\/jats:title>\n                    <jats:p>The primary outcome of PIPAC-OPC2 is to evaluate if PIPAC can induce major or complete response (PRGS 1 or 2) within a series of three PIPAC procedures. Secondarily this study investigates changes in QoL and MRI as a staging and response evaluation tool. The secondary outcomes will be used to create a model that may predict which of the patients will benefit from PIPAC treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2018-0108_s_004_w2aab3b7b2b1b6b1aab1c17b4Aa\">\n                    <jats:title id=\"d8956950e2928_w2aab3b7b2b1b6b1aab1c17b4aAa\">Conclusions<\/jats:title>\n                    <jats:p>It is expected that PIPAC directed therapy can induce major or complete response in 50\u2006% of patients with PC of colorectal origin and in 30\u2006% of patients with PC of non-colorectal origin \u2013 and at the same time stabilize or even improve quality of life. This trial may provide data regarding the utility of MRI as a staging and response evaluation tool in patients with PC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2018-0108_s_005_w2aab3b7b2b1b6b1aab1c17b5Aa\">\n                    <jats:title id=\"d8956950e2938_w2aab3b7b2b1b6b1aab1c17b5aAa\">Trial registration<\/jats:title>\n                    <jats:p>The study is registered with ClinicalTrials.gov Identifier NCT03287375 and the European Clinical Trials Database (EudraCT) number 2016-003394-18.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2018-0108","type":"journal-article","created":{"date-parts":[[2018,6,9]],"date-time":"2018-06-09T18:16:39Z","timestamp":1528568199000},"source":"Crossref","is-referenced-by-count":29,"title":["Treatment of peritoneal carcinomatosis with Pressurized IntraPeritoneal Aerosol Chemotherapy \u2013 PIPAC-OPC2"],"prefix":"10.1515","volume":"3","author":[{"given":"Martin","family":"Graversen","sequence":"first","affiliation":[{"name":"Odense PIPAC Center (OPC) and Odense Pancreas Center (OPAC) HPB and Upper GI Section, Department of Surgery , Odense University Hospital , Odense , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6nke","family":"Detlefsen","sequence":"additional","affiliation":[{"name":"Odense PIPAC Center (OPC) and Odense Pancreas Center (OPAC), Department of Pathology , Odense University Hospital , Odense , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Asmussen","sequence":"additional","affiliation":[{"name":"Odense PIPAC Center (OPC) and Odense Pancreas Center (OPAC), Department of Radiology , Odense University Hospital , Odense , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassam","family":"Mahdi","sequence":"additional","affiliation":[{"name":"Odense PIPAC Center (OPC) and Odense Pancreas Center (OPAC), Department of Radiology , Odense University Hospital , Odense , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Fristrup","sequence":"additional","affiliation":[{"name":"Odense PIPAC Center (OPC) and Odense Pancreas Center (OPAC) HPB and Upper GI Section, Department of Surgery , Odense University Hospital , Odense , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Pfeiffer","sequence":"additional","affiliation":[{"name":"Odense PIPAC Center (OPC) and Odense Pancreas Center (OPAC), Department of Oncology , Odense University Hospital , Odense , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Bau","family":"Mortensen","sequence":"additional","affiliation":[{"name":"Odense PIPAC Center (OPC) and Odense Pancreas Center (OPAC) HPB and Upper GI Section, Department of Surgery , Odense University Hospital , Odense , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2018,6,9]]},"reference":[{"key":"2025120909215701905_j_pp-2018-0108_ref_001_w2aab3b7b2b1b6b1ab1b4b1Aa","doi-asserted-by":"crossref","unstructured":"Coccolini F, Gheza F, Lotti M, Virzi S, Iusco D, Ghermandi C, et al. Peritoneal carcinomatosis. Wjg 2013;19:6979\u201394.10.3748\/wjg.v19.i41.6979","DOI":"10.3748\/wjg.v19.i41.6979"},{"key":"2025120909215701905_j_pp-2018-0108_ref_002_w2aab3b7b2b1b6b1ab1b4b2Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol 1998;14:254\u201361.10.1002\/(SICI)1098-2388(199804\/05)14:3<254::AID-SSU10>3.0.CO;2-U9548609","DOI":"10.1002\/(SICI)1098-2388(199804\/05)14:3<254::AID-SSU10>3.0.CO;2-U"},{"key":"2025120909215701905_j_pp-2018-0108_ref_003_w2aab3b7b2b1b6b1ab1b4b3Aa","doi-asserted-by":"crossref","unstructured":"Solass W, Giger-Pabst U, Zieren J, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC): occupational health and safety aspects. Ann Surg Oncol 2013;20:3504\u201311.2376541710.1245\/s10434-013-3039-x","DOI":"10.1245\/s10434-013-3039-x"},{"key":"2025120909215701905_j_pp-2018-0108_ref_004_w2aab3b7b2b1b6b1ab1b4b4Aa","doi-asserted-by":"crossref","unstructured":"Graversen M, Pedersen P, Mortensen MB. Environmental safety during the administration of pressurized intraperitoneal aerosol chemotherapy. Pleura and Peritoneum 2016;1:203\u20138.","DOI":"10.1515\/pp-2016-0019"},{"key":"2025120909215701905_j_pp-2018-0108_ref_005_w2aab3b7b2b1b6b1ab1b4b5Aa","doi-asserted-by":"crossref","unstructured":"Blanco A, Giger-Pabst U, Solass W, Zieren J, Reymond MA. Renal and hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy (PIPAC). Ann Surg Oncol 2013;20:2311\u20136.10.1245\/s10434-012-2840-223377563","DOI":"10.1245\/s10434-012-2840-2"},{"key":"2025120909215701905_j_pp-2018-0108_ref_006_w2aab3b7b2b1b6b1ab1b4b6Aa","doi-asserted-by":"crossref","unstructured":"Nadiradze G, Giger-Pabst U, Zieren J, Strumberg D, Solass W, Reymond MA. Pressurized Intraperitoneal aerosol chemotherapy (PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis. J Gastrointestinal Surg: Off J Soc Surg Alimentary Tract 2016;20:367\u201373.10.1007\/s11605-015-2995-9","DOI":"10.1007\/s11605-015-2995-9"},{"key":"2025120909215701905_j_pp-2018-0108_ref_007_w2aab3b7b2b1b6b1ab1b4b7Aa","doi-asserted-by":"crossref","unstructured":"Tempfer CB, Winnekendonk G, Solass W, Horvat R, Giger-Pabst U, Zieren J, et al. Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: A phase 2 study. Gynecol Oncol 2015;137:223\u20138.10.1016\/j.ygyno.2015.02.00925701703","DOI":"10.1016\/j.ygyno.2015.02.009"},{"key":"2025120909215701905_j_pp-2018-0108_ref_008_w2aab3b7b2b1b6b1ab1b4b8Aa","doi-asserted-by":"crossref","unstructured":"Grass F, Vuagniaux A, Teixeira-Farinha H, Lehmann K, Demartines N, Hubner M. Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis. Br J Surg 2017;104:669\u201378.10.1002\/bjs.1052128407227","DOI":"10.1002\/bjs.10521"},{"key":"2025120909215701905_j_pp-2018-0108_ref_009_w2aab3b7b2b1b6b1ab1b4b9Aa","doi-asserted-by":"crossref","unstructured":"Nowacki M, Alyami M, Villeneuve L, Mercier F, Hubner M, Willaert W, et al. Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: an international survey study. Eur J Surg Oncol 2018. https:\/\/doi.org\/10.1016\/j.ejso.2018.02.014.29526367","DOI":"10.1016\/j.ejso.2018.02.014"},{"key":"2025120909215701905_j_pp-2018-0108_ref_010_w2aab3b7b2b1b6b1ab1b4c10Aa","doi-asserted-by":"crossref","unstructured":"Solass W, Sempoux C, Detlefsen S, Carr NJ, Bibeau F. Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the peritoneal regression grading score (PRGS). Pleura and Peritoneum 2016;1:99\u2013107.","DOI":"10.1515\/pp-2016-0011"},{"key":"2025120909215701905_j_pp-2018-0108_ref_011_w2aab3b7b2b1b6b1ab1b4c11Aa","doi-asserted-by":"crossref","unstructured":"Badgwell B, Cormier JN, Krishnan S, Yao J, Staerkel GA, Lupo PJ, et al. Does neoadjuvant treatment for gastric cancer patients with positive peritoneal cytology at staging laparoscopy improve survival? Ann Surg Oncol 2008;15:2684\u201391.10.1245\/s10434-008-0055-318649106","DOI":"10.1245\/s10434-008-0055-3"},{"key":"2025120909215701905_j_pp-2018-0108_ref_012_w2aab3b7b2b1b6b1ab1b4c12Aa","doi-asserted-by":"crossref","unstructured":"Michielsen K, Vergote I, Op De Beeck K, Amant F, Leunen K, Moerman P, et al. Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET\/CT. Eur Radiol 2014;24:889\u2013901.10.1007\/s00330-013-3083-8","DOI":"10.1007\/s00330-013-3083-8"},{"key":"2025120909215701905_j_pp-2018-0108_ref_013_w2aab3b7b2b1b6b1ab1b4c13Aa","doi-asserted-by":"crossref","unstructured":"Low RN, Barone RM. Combined diffusion-weighted and gadolinium-enhanced MRI can accurately predict the peritoneal cancer index preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol 2012;19:1394\u2013401.10.1245\/s10434-012-2236-322302265","DOI":"10.1245\/s10434-012-2236-3"},{"key":"2025120909215701905_j_pp-2018-0108_ref_014_w2aab3b7b2b1b6b1ab1b4c14Aa","doi-asserted-by":"crossref","unstructured":"Low RN, Barone RM, Lucero J. Comparison of MRI and CT for predicting the peritoneal cancer index (PCI) preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol 2015;22:1708\u201315.10.1245\/s10434-014-4041-725201499","DOI":"10.1245\/s10434-014-4041-7"},{"key":"2025120909215701905_j_pp-2018-0108_ref_015_w2aab3b7b2b1b6b1ab1b4c15Aa","doi-asserted-by":"crossref","unstructured":"Sun K, Chen S, Xu J, Li G, He Y. The prognostic significance of the prognostic nutritional index in cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2014;140:1537\u201349.10.1007\/s00432-014-1714-3","DOI":"10.1007\/s00432-014-1714-3"},{"key":"2025120909215701905_j_pp-2018-0108_ref_016_w2aab3b7b2b1b6b1ab1b4c16Aa","doi-asserted-by":"crossref","unstructured":"Jiang N, Deng JY, Ding XW, Ke B, Liu N, Zhang RP, et al. Prognostic nutritional index predicts postoperative complications and long-term outcomes of gastric cancer. Wjg 2014;20:10537\u201344.10.3748\/wjg.v20.i30.10537","DOI":"10.3748\/wjg.v20.i30.10537"},{"key":"2025120909215701905_j_pp-2018-0108_ref_017_w2aab3b7b2b1b6b1ab1b4c17Aa","doi-asserted-by":"crossref","unstructured":"Nozoe T, Ninomiya M, Maeda T, Matsukuma A, Nakashima H, Ezaki T. Prognostic nutritional index: a tool to predict the biological aggressiveness of gastric carcinoma. Surg Today 2010;40:440\u20133.10.1007\/s00595-009-4065-y20425547","DOI":"10.1007\/s00595-009-4065-y"},{"key":"2025120909215701905_j_pp-2018-0108_ref_018_w2aab3b7b2b1b6b1ab1b4c18Aa","doi-asserted-by":"crossref","unstructured":"Bottomley A, Aaronson NK. International perspective on health-related quality-of-life research in cancer clinical trials: the european organisation for research and treatment of cancer experience. J Clin Oncol 2007;25:5082\u20136.10.1200\/JCO.2007.11.318317991925","DOI":"10.1200\/JCO.2007.11.3183"},{"key":"2025120909215701905_j_pp-2018-0108_ref_019_w2aab3b7b2b1b6b1ab1b4c19Aa","doi-asserted-by":"crossref","unstructured":"Chang HH, Leeper WR, Chan G, Quan D, Driman DK. Infarct-like necrosis: a distinct form of necrosis seen in colorectal carcinoma liver metastases treated with perioperative chemotherapy. Am J Surg Pathol 2012;36:570\u20136.10.1097\/PAS.0b013e31824057e722301494","DOI":"10.1097\/PAS.0b013e31824057e7"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/3\/2\/article-20180108.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2018-0108\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2018-0108\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:54:17Z","timestamp":1765277657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2018-0108\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,6,12]]},"published-print":{"date-parts":[[2018,6,26]]}},"alternative-id":["10.1515\/pp-2018-0108"],"URL":"https:\/\/doi.org\/10.1515\/pp-2018-0108","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6,1]]},"article-number":"20180108"}}